インターベンションオンコロジー市場 – 2029年までの世界予測

Report Overview

The interventional oncology market is projected to reach USD 4.24 billion by 2029 from USD 2.75 billion in 2024, at a CAGR of 9.0% during the forecast period.

インターベンションオンコロジー市場は、予測期間中のCAGR 9.0%で、2024年の27億5,000万米ドルから2029年までに42億4,000万米ドルに達すると予測されています。

Interventional oncology, has seen significant growth over the past decade. Progress in minimally invasive techniques and an increase in cancer prevalence rates have contributed significantly to this boom. Initially, the market for interventional oncology was underdeveloped owing to the long-standing use of traditional surgical approaches for cancer; however, growing evidence of safety and efficacy from interventional treatments like TACE, TARE, and thermal ablation sparked interest in using these treatments. These techniques have many advantages, such as shorter recovery times, fewer complications, and better overall patient outcomes compared to conventional surgery. The increasing demand for effective treatments for inoperable tumors, especially liver, lung, and kidney cancers, has driven the growth of the market.

“By devices & consumables, embolization devices segment is expected to have the largest market share in the interventional oncology market.”

Based on devices & consumables, the market share of embolization devices in the interventional oncology sector is highest, as these are crucial tools in minimally invasive cancer treatments that provide an overwhelming advantage over conventional surgical methods. These devices act by reducing or cutting off the blood flow to the tumor, thus starving the tumor of the oxygen and nutrients needed for growth. The growing trend of embolization procedures, TACE, and radioembolization, which is also called selective internal radiation therapy, can be attributed to their proven success in the treatment of inoperable cancers, especially liver cancer, which remains a significant concern in interventional oncology. Improvements in embolic agents, including drug-eluting beads and radioactive microspheres, have improved accuracy and therapeutic outcomes and are therefore becoming more popular. Such factors as the increased global incidence of cancer, increased awareness of non-invasive treatment options, and shift towards outpatient care models further contribute to the growing use of such devices.

“By cancer type, liver cancer segment is expected to have the largest market share in the interventional oncology market.”

Based on cancer type, liver cancer is the biggest market share in the interventional oncology segment, primarily due to its increasing global incidence, high mortality rate, and the urgent need for effective, minimally invasive treatment solutions. Hepatocellular carcinoma, the most common form of liver cancer, is closely associated with risk factors such as chronic hepatitis B and C infections, excessive alcohol use, and the growing prevalence of non-alcoholic fatty liver disease. Targeted treatments such as TACE, TARE, and percutaneous ablation in interventional oncology have been very effective in the treatment of unresectable liver cancers. These interventions provide localized tumor control, reduced systemic toxicity, and improved survival outcomes compared to traditional chemotherapy.

“By procedure, transcatheter arterial radioembolization (TARE) or selective internal radiation therapy (SIRT) segment is expected to have the largest market share in the interventional oncology market.”

Based on procedure, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable.

“By end user, hospitals segment is expected to have the largest market share in the interventional oncology market.”

Based on end user, transcatheter arterial radioembolization (TARE), also referred to as selective internal radiation therapy (SIRT), holds the largest market share in the interventional oncology sector due to its demonstrated efficacy in managing both primary and secondary liver cancers, which account for a significant portion of cancer-related mortalities worldwide. This procedure involves injecting microspheres that are infused with radioactive isotopes, most commonly Yttrium-90, directly into the hepatic artery that feeds the tumor. TARE is effective in killing tumor cells with minimal systemic exposure and reduced damage to healthy surrounding tissues by delivering localized radiation. It is becoming increasingly popular because of a superior safety profile, enhanced tolerability, and fewer adverse effects than conventional chemotherapy and external beam radiation therapy. In addition, TARE is particularly useful in patients with unresectable hepatocellular carcinoma and liver metastases from colorectal cancer, in whom alternative treatments are less effective or unavailable.

“By region, North America region is expected to have the largest market share in the interventional oncology market.”

The market share of interventional oncology is dominated by hospitals because of their wide infrastructure, latest technology, and multidisciplinary expertise necessary to perform advanced interventional procedures. Techniques such as TACE, TARE, and tumor ablation are highly specialized and minimally invasive and require access to sophisticated imaging systems, catheterization laboratories, and experienced interventional radiologists. Tertiary care centers and dedicated cancer hospitals have more of such facilities, so these are ideally placed as the first option for interventional oncology treatment. Additionally, a hospital would offer complete treatment; it offers diagnosis, treatment, post-treatment care, and follow-up. This helps in attracting the wide patient spectrum looking for one-stop solutions to treat cancer.

A breakdown of the primary participants (supply-side) for the interventional oncology market referred to for this report is provided below:

• By Company Type: Tier 1–35%, Tier 2–40%, and Tier 3–25%
• By Designation: C-level–20%, Director Level–35%, and Others–45%
• By Region: North America–27%, Europe–25%, Asia Pacific–30%, Latin America- 8%, Middle East & Africa-10% .

Prominent players in the interventional oncology market are are Siemens Healthineers AG (Varian) (US), Medtronic (Ireland), Boston Scientific Corporation (US), Terumo Corporation (Japan), Merit Medical Systems (US), Johnson & Johnson MedTech (Ethicon) (US), Stryker (US), Teleflex Incorporated (US), AngioDynamics (US), Cook (US), Icecure Medical (Israel), Olympus Corporation (Japan), Imbiotechnologies Ltd (Canada), Medwaves Inc (US), Minimax Medical Limited (China), ABK Biomedical Inc (Canada), RF Medical Co., Ltd (South Korea), Profound Medical (Canada), Surgnova (China), STARmed America (US), Sirtex SIR-Spheres Pty Ltd (US), Accuray Incorporated (US), Guerbet (France), Embolx, Inc (Canada) and Sonablate Corp (US).

Research Coverage:

The report analyzes the interventional oncology market and aims at estimating the market size and future growth potential of this market based on various segments such as devices & consumables, cancer type, procedure, end user and region. The report also includes a competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Analysis of key drivers (Rising patient preference for minimally invasive procedure, expansion of cancer patient population, increasing public-private funding and government support for interventional oncology, technological advancements in interventional oncology), restraints (High cost of interventional oncology, unfavorable regulations), opportunities (emerging economies offer high growth potential), challenges (dearth of well-trained and skilled radiologist and oncologist, strong market positioning of alternative therapies)
• ZMarket Penetration: It includes extensive information on products offered by the major players in the global the interventional oncology market. The report includes various segments in offering, application, end user and region.
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional oncology market.
• Market Development: Thorough knowledge and analysis of the profitable rising markets by offering, application, end user and region.
• Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global the interventional oncology market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products, and capacities of the major competitors in the global interventional oncology market.

Table of Contents

1               INTRODUCTION              38

1.1           STUDY OBJECTIVES       38

1.2           MARKET DEFINITION & SCOPE 38

1.2.1        INCLUSIONS & EXCLUSIONS       39

1.2.2        MARKETS COVERED       40

1.2.3        YEARS CONSIDERED      41

1.2.4        CURRENCY CONSIDERED            41

1.3           STAKEHOLDERS               42

1.4           LIMITATIONS    42

1.5           SUMMARY OF CHANGES               42

2               RESEARCH METHODOLOGY       44

2.1           RESEARCH DATA              44

2.1.1        SECONDARY DATA          45

2.1.1.1    Key data from secondary sources       46

2.1.2        PRIMARY DATA 47

2.1.2.1    Key data from primary sources           48

2.1.2.2    Key industry insights           49

2.2           MARKET SIZE ESTIMATION         51

2.3           MARKET BREAKDOWN AND DATA TRIANGULATION                 57

2.4           MARKET SHARE ESTIMATION    58

2.5           STUDY ASSUMPTIONS  58

2.6           RESEARCH LIMITATIONS             58

2.6.1        METHODOLOGY-RELATED LIMITATIONS           58

2.7           RISK ASSESSMENT           59

3               EXECUTIVE SUMMARY  60

4               PREMIUM INSIGHTS       65

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET              65

4.2           ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES AND COUNTRY, 2023        66

4.3           INTERVENTIONAL ONCOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         67

4.4           INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024−2029            67

4.5           INTERVENTIONAL ONCOLOGY MARKET: DEVELOPED VS. EMERGING MARKETS              68

5               MARKET OVERVIEW       69

5.1           INTRODUCTION              69

5.2           MARKET DYNAMICS       69

5.2.1        DRIVERS               70

5.2.1.1    Rising preference for minimally invasive procedures     70

5.2.1.2    Growing prevalence of cancer            70

5.2.1.3    Increasing public-private funding and government support for interventional oncology       71

5.2.1.4    Technological advancements in interventional oncology                 71

5.2.2        RESTRAINTS      72

5.2.2.1    High cost of interventional oncology 72

5.2.2.2    Unfavorable regulations      72

5.2.3        OPPORTUNITIES              73

5.2.3.1    Emerging economies offer high-growth potential           73

5.2.4        CHALLENGES    73

5.2.4.1    Dearth of well-trained and skilled radiologists and oncologists                 73

5.2.4.2    Strong market position of alternative therapies               74

5.3           INDUSTRY TRENDS         74

5.3.1        INNOVATIONS IN IMAGING AND TREATMENT TECHNOLOGIES               74

5.3.2        INCREASING ADOPTION OF MINIMALLY INVASIVE PROCEDURES    74

5.4           VALUE CHAIN ANALYSIS               75

5.5           TECHNOLOGY ANALYSIS             76

5.5.1        KEY TECHNOLOGIES     76

5.5.1.1    Ablation technologies           76

5.5.1.2    Embolization technologies  76

5.5.2        COMPLEMENTARY TECHNOLOGY           76

5.5.2.1    Laparoscopy          76

5.5.2.2    Diagnostic imaging               76

5.5.3        ADJACENT TECHNOLOGY           77

5.5.3.1    Radiation therapy systems  77

5.5.3.2    Chemotherapy       77

5.6           PORTER’S FIVE FORCES ANALYSIS           77

5.6.1        THREAT OF NEW ENTRANTS      78

5.6.2        THREAT OF SUBSTITUTES          78

5.6.3        BARGAINING POWER OF SUPPLIERS       78

5.6.4        BARGAINING POWER OF BUYERS             78

5.6.5        INTENSITY OF COMPETITIVE RIVALRY 79

5.7           KEY STAKEHOLDERS AND BUYING CRITERIA     79

5.7.1        KEY STAKEHOLDERS IN BUYING PROCESS           79

5.7.2        BUYING CRITERIA           80

5.8           REGULATORY LANDSCAPE         81

5.8.1        KEY REGULATORY BODIES AND GOVERNMENT AGENCIES           81

5.8.2        KEY REGULATORY GUIDELINES               84

5.8.2.1    US           84

5.8.2.2    Canada   85

5.8.2.3    Europe   87

5.8.2.4    Asia Pacific            88

5.8.2.4.1 Japan      88

5.8.2.4.2 China      90

5.8.2.4.3 India       91

5.8.2.5    Brazil      92

5.9           TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       93

5.10         PATENT ANALYSIS          93

5.10.1      PATENT PUBLICATION TRENDS FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024      93

5.11         TRADE ANALYSIS             96

5.12         PRICING ANALYSIS          97

5.12.1      AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,

BY KEY PLAYER, 2023      97

5.12.2      AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,

BY KEY PLAYER, 2023 (USD)         97

5.12.3      AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES, BY REGION, 2021–2023      98

5.13         KEY CONFERENCES AND EVENTS, 2025–2026        99

5.14         UNMET NEEDS AND END USER EXPECTATIONS                 100

5.14.1      UNMET NEEDS 100

5.15         END USER EXPECTATIONS IN INTERVENTIONAL ONCOLOGY MARKET     101

5.16         ECOSYSTEM       102

5.17         CASE STUDIES  103

5.18         SUPPLY CHAIN ANALYSIS             104

5.19         ADJACENT MARKET ANALYSIS  105

5.20         INTERVENTIONAL ONCOLOGY MARKET, INVESTMENT AND FUNDING SCENARIO,

2020–2023              106

5.21         IMPACT OF GENERATIVE AI ON INTERVENTIONAL ONCOLOGY MARKET     106

6               INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES 107

6.1           INTRODUCTION              108

6.2           EMBOLIZATION DEVICES            108

6.2.1        RADIOEMBOLIC AGENTS             112

6.2.1.1    Precision-targeted therapy for challenging liver cancers to boost market    112

6.2.2        NON-RADIOACTIVE EMBOLIC AGENTS 115

6.2.2.1    Non-radiation emitting agents to propel market             115

6.2.2.2    Microspheres         119

6.2.2.2.1 Surge in prevalence of hepatocellular carcinoma to fuel growth                 119

6.2.2.3    Coated beads         122

6.2.2.3.1 Specialized polymer coatings with enhanced ability to bind, absorb, and release chemotherapeutic agents to drive market      122

6.2.2.4    Microparticles       125

6.2.2.4.1 Use in various cancer applications to drive growth         125

6.3           ABLATION DEVICES       128

6.3.1        RADIOFREQUENCY (RF) ABLATION DEVICES     131

6.3.1.1    Effective treatment of small or difficult-to-reach tumors to propel market growth       131

6.3.2        MICROWAVE ABLATION DEVICES            134

6.3.2.1    Simultaneous treatment of multiple lesions to drive market growth    134

6.3.3        CRYOABLATION DEVICES            137

6.3.3.1    Least painful and higher patient compatibility to drive market                 137

6.3.4        OTHER ABLATION DEVICES       140

6.4           SUPPORT DEVICES         143

6.4.1        MICROCATHETERS         146

6.4.1.1    Precise delivery of therapeutic agents to tumors to boost market                 146

6.4.2        GUIDEWIRES     149

6.4.2.1    Advancements in guidewire construction and launch of new and advanced products to propel market 149

6.4.3        OTHER SUPPORT DEVICES         151

7               INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE     154

7.1           INTRODUCTION              155

7.2           LIVER CANCER  156

7.2.1        INCREASING DISEASE PREVALENCE AND RISING RESEARCH ACTIVITIES TO DRIVE MARKET GROWTH     156

7.3           KIDNEY CANCER              159

7.3.1        FIRST-LINE THERAPY PRESERVING MORE KIDNEY TISSUE THAN SURGERY TO BOOST MARKET      159

7.4           BREAST CANCER              162

7.4.1        HIGH PRECISION, BETTER COSMETIC OUTCOMES, COST-EFFECTIVENESS, AND GREATER PATIENT COMFORT TO PROPEL MARKET             162

7.5           LUNG CANCER  165

7.5.1        INCREASING NUMBER OF CANCER CASES TO DRIVE DEMAND             165

7.6           BONE CANCER  168

7.6.1        DIRECT ELIMINATION OF TUMORS AND PAIN RELIEF TO FUEL MARKET            168

7.7           PROSTATE CANCER        171

7.7.1        RISING INCIDENCE OF PROSTATE CANCER AND GROWING ADOPTION OF METAL-BASED FIDUCIAL MARKERS TO CONTRIBUTE TO MARKET GROWTH               171

7.8           OTHER CANCER TYPES 174

8               INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE      177

8.1           INTRODUCTION              178

8.2           TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)  179

8.2.1        GREATER CLINICAL EFFICACY TO DRIVE MARKET GROWTH             179

8.3           TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) 182

8.3.1        ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS TO DRIVE DEMAND        182

8.4           TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)  185

8.4.1        INCREASING CLINICAL EVIDENCE IN FAVOR OF TARE AND TACE TO RESTRAIN MARKET GROWTH      185

8.5           THERMAL TUMOR ABLATION   188

8.5.1        GROWING CLINICAL EVIDENCE PROVING EFFICACY OF TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH          188

8.6           NON-THERMAL TUMOR ABLATION        191

8.6.1        POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TO BOOST MARKET 191

9               INTERVENTIONAL ONCOLOGY MARKET, BY END USER                 194

9.1           INTRODUCTION              195

9.2           HOSPITALS         195

9.2.1        INCREASING NUMBER OF SURGERIES IN IN-PATIENT SETTINGS TO SUPPORT MARKET GROWTH        195

9.3           SPECIALTY CLINICS        199

9.3.1        INCREASING NUMBER OF CANCER CENTERS TO DRIVE MARKET GROWTH          199

9.4           RESEARCH & ACADEMIC INSTITUTES    202

9.4.1        COLLABORATIONS AMONG DEVICE MANUFACTURERS AND SUPPLIERS TO FUEL MARKET          202

10            INTERVENTIONAL ONCOLOGY MARKET, BY REGION                 205

10.1         INTRODUCTION              206

10.2         NORTH AMERICA             208

10.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 215

10.2.2      US           216

10.2.2.1  Rising cancer cases and preference for ablation procedures to boost market          216

10.2.3      CANADA               223

10.2.3.1  Significant rise in cancer cases to drive market growth  223

10.3         EUROPE               229

10.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      238

10.3.2      GERMANY           239

10.3.2.1  Increase in incidence of cancer and rising geriatric population to fuel market             239

10.3.3      UK          245

10.3.3.1  Increasing awareness and support for cancer-related activities to drive market          245

10.3.4      FRANCE                252

10.3.4.1  Growing geriatric population to support market growth                 252

10.3.5      SPAIN    258

10.3.5.1  Increasing government funding for research to support market growth    258

10.3.6      ITALY    265

10.3.6.1  Growing awareness about cancer and treatment options to support market growth        265

10.3.7      REST OF EUROPE             271

10.4         ASIA PACIFIC     278

10.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 287

10.4.2      JAPAN   288

10.4.2.1  Rising geriatric population and universal healthcare reimbursement to drive market          288

10.4.3      CHINA  294

10.4.3.1  Increasing incidence of cancer to drive market                294

10.4.4      INDIA    301

10.4.4.1  Improving research capabilities and expansion of key players to drive market growth             301

10.4.5      AUSTRALIA         307

10.4.5.1  Rising investments in research and awareness campaigns to support market growth        307

10.4.6      SOUTH KOREA  314

10.4.6.1  Rising R&D and promising clinical trials to positively impact market growth       314

10.4.7      REST OF ASIA PACIFIC   320

10.5         LATIN AMERICA                327

10.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 334

10.5.2      BRAZIL 335

10.5.2.1  Rising incidence of cancer and improving healthcare infrastructure to fuel market               335

10.5.3      MEXICO                341

10.5.3.1  Increasing awareness campaigns and rising incidence of cancer to drive market growth             341

10.5.4      REST OF LATIN AMERICA             348

10.6         MIDDLE EAST & AFRICA                354

10.6.1      MACROECONOMIC OUTLOOK  361

10.6.2      GCC COUNTRIES              362

10.6.2.1  Broader healthcare modernization initiatives in interventional oncology to drive market     362

10.6.3      REST OF MIDDLE EAST & AFRICA             369

11            COMPETITIVE LANDSCAPE         376

11.1         OVERVIEW          376

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021–2024                 376

11.3         REVENUE ANALYSIS, 2019−2023                 378

11.4         MARKET SHARE ANALYSIS, 2023                 379

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 382

11.5.1      STARS   382

11.5.2      EMERGING LEADERS     382

11.5.3      PERVASIVE PLAYERS      382

11.5.4      PARTICIPANTS 382

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         384

11.5.5.1  Company footprint               384

11.5.5.2  Region footprint   385

11.5.5.3  Devices & Consumables footprint     386

11.5.5.4  Cancer type footprint           387

11.5.5.5  Procedure footprint              389

11.5.5.6  End user footprint                 390

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        391

11.6.1      PROGRESSIVE COMPANIES         391

11.6.2      DYNAMIC COMPANIES  391

11.6.3      STARTING BLOCKS         391

11.6.4      RESPONSIVE COMPANIES            391

11.6.5      COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, 2023   393

11.6.5.1  Detailed list of key startups/SMES, 2023         393

11.6.5.2  Competitive benchmarking of key startups/SMEs          393

11.7         VALUATION & FINANCIAL METRICS       394

11.7.1      FINANCIAL METRICS      394

11.7.2      COMPANY VALUATION 394

11.8         BRAND COMPARISON   395

11.9         COMPETITIVE SCENARIO             396

11.9.1      PRODUCT & SERVICE LAUNCHES AND APPROVALS                 396

11.9.2      DEALS  396

11.9.3      EXPANSIONS     398

12            COMPANY PROFILES      399

12.1         KEY PLAYERS     399

12.1.1      SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC)  399

12.1.1.1  Business overview 399

12.1.1.2  Products/Solutions/Services offered 400

12.1.1.3  Recent developments           401

12.1.1.3.1                Product launches & approvals            401

12.1.1.3.2                Deals      401

12.1.1.4  MnM view              402

12.1.1.4.1                Right to win           402

12.1.1.4.2                Strategic choices   403

12.1.1.4.3                Weaknesses and competitive threats 403

12.1.2      BOSTON SCIENTIFIC CORPORATION     404

12.1.2.1  Business overview 404

12.1.2.2  Products/Solutions/Services offered 405

12.1.2.3  Recent developments           406

12.1.2.3.1                Product launches & approvals            406

12.1.2.3.2                Deals      407

12.1.2.4  MnM view              407

12.1.2.4.1                Right to win           407

12.1.2.4.2                Strategic choices   407

12.1.2.4.3                Weaknesses and competitive threats 407

12.1.3      MEDTRONIC      408

12.1.3.1  Business overview 408

12.1.3.2  Products/Solutions/Services offered 409

12.1.3.3  MnM view              411

12.1.3.3.1                Right to win           411

12.1.3.3.2                Strategic choices   411

12.1.3.3.3                Weaknesses and competitive threats 411

12.1.4      TERUMO CORPORATION             412

12.1.4.1  Business overview 412

12.1.4.2  Products/Solutions/Services offered 413

12.1.4.3  Recent developments           414

12.1.4.3.1                Expansions             414

12.1.4.4  MnM view              414

12.1.4.4.1                Right to win           414

12.1.4.4.2                Strategic choices   414

12.1.4.4.3                Weaknesses and competitive threats 414

12.1.5      MERIT MEDICAL SYSTEMS           415

12.1.5.1  Business overview 415

12.1.5.2  Products/Solutions/Services offered 416

12.1.5.3  Recent developments           417

12.1.5.3.1                Expansions             417

12.1.5.4  MnM view              417

12.1.5.4.1                Right to win           417

12.1.5.4.2                Strategic choices   418

12.1.5.4.3                Weaknesses and competitive threats 418

12.1.6      JOHNSON & JOHNSON MEDTECH (ETHICON)    419

12.1.6.1  Business overview 419

12.1.6.2  Products/Solutions/Services offered 420

12.1.7      TELEFLEX INCORPORATED        421

12.1.7.1  Business overview 421

12.1.7.2  Products/Solutions/Services offered 422

12.1.8      ANGIODYNAMICS            423

12.1.8.1  Business overview 423

12.1.8.2  Products/Solutions/Services offered 424

12.1.8.3  Recent developments           425

12.1.8.3.1                Product launches & approvals            425

12.1.9      STRYKER              426

12.1.9.1  Business overview 426

12.1.9.2  Products/Solutions/Services offered 427

12.1.10   IMBIOTECHNOLOGIES LTD.       428

12.1.10.1                 Business overview 428

12.1.10.2                 Products/Solutions/Services offered 428

12.1.11   COOK    429

12.1.11.1                 Business overview 429

12.1.11.2                 Products/Solutions/Services offered 429

12.1.12   ICECURE MEDICAL         430

12.1.12.1                 Business overview 430

12.1.12.2                 Products/Solutions/Services offered 431

12.1.12.3                 Recent developments           432

12.1.12.3.1             Product approvals 432

12.1.12.3.2             Deals      432

12.1.13   MEDWAVES, INC.              434

12.1.13.1                 Business overview 434

12.1.13.2                 Products/Solutions/Services offered 434

12.1.14   PROFOUND MEDICAL   435

12.1.14.1                 Business overview 435

12.1.14.2                 Products/Solutions/Services offered 435

12.1.15   RF MEDICAL CO., LTD.  436

12.1.15.1                 Business overview 436

12.1.15.2                 Products/Solutions/Services offered 436

12.1.16   MINIMAX MEDICAL LIMITED     437

12.1.16.1                 Business overview 437

12.1.16.2                 Products/Solutions/Services offered 437

12.1.17   ABK BIOMEDICAL INC.  438

12.1.17.1                 Business overview 438

12.1.17.2                 Products/Solutions/Services offered 438

12.1.18   OLYMPUS CORPORATION           439

12.1.18.1                 Business overview 439

12.1.18.2                 Products/Solutions/Services offered 440

12.1.19   SURGNOVA         441

12.1.19.1                 Business overview 441

12.1.19.2                 Products/Solutions/Services offered 441

12.1.20   STARMED AMERICA        442

12.1.20.1                 Business overview 442

12.1.20.2                 Products/Solutions/Services offered 442

12.2         OTHER PLAYERS              443

12.2.1      SIRTEX SIR-SPHERES PTY LTD.  443

12.2.2      GUERBET            444

12.2.3      ACCURAY INCORPORATED         445

12.2.4      EMBOLX, INC.   446

12.2.5      SONABLATE CORP.         447

13            APPENDIX           448

13.1         DISCUSSION GUIDE        448

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                452

13.3         CUSTOMIZATION OPTIONS        454

13.4         RELATED REPORTS         454

13.5         AUTHOR DETAILS           455

LIST OF TABLES

TABLE 1                STANDARD CURRENCY CONVERSION RATES                 41

TABLE 2                RISK ASSESSMENT: INTERVENTIONAL ONCOLOGY MARKET     59

TABLE 3                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES               79

TABLE 4                KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES                 80

TABLE 5                NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 81

TABLE 6                EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES            81

TABLE 7                ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 82

TABLE 8                LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES 83

TABLE 9                MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND

GOVERNMENT AGENCIES            83

TABLE 10              US FDA: MEDICAL DEVICE CLASSIFICATION                 84

TABLE 11              US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              84

TABLE 12              CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      85

TABLE 13              JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES              89

TABLE 14              JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)                 89

TABLE 15              CHINA: CLASSIFICATION OF MEDICAL DEVICES                 90

TABLE 16              INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES              92

TABLE 17              LIST OF PATENTS IN INTERVENTIONAL ONCOLOGY MARKET, 2021–2024                95

TABLE 18              IMPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)      96

TABLE 19              EXPORT DATA FOR INTERVENTIONAL ONCOLOGY (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)      96

TABLE 20              AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,

BY KEY PLAYER, 2023 (USD)         97

TABLE 21              AVERAGE SELLING PRICE TREND OF INTERVENTIONAL ONCOLOGY DEVICES,

BY REGION, 2021–2023    98

TABLE 22              INTERVENTIONAL ONCOLOGY MARKET: KEY CONFERENCES & EVENTS,

2025–2026              99

TABLE 23              END USER EXPECTATIONS FOR EMBOLIZATION DEVICES, ABLATION DEVICES,

AND SUPPORT DEVICES               101

TABLE 24              INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM ANALYSIS  102

TABLE 25              TREATMENT OF HEPATOCELLULAR CARCINOMA WITH ARTERIOPORTAL SHUNTING USING BALLOON-ASSISTED TRANSARTERIAL YTTRIUM-90 RADIATION SEGMENTECTOMY         103

TABLE 26              RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY  104

TABLE 27              UPPER POLE ANGIOMYOLIPOMA (AML) EMBOLIZATION               104

TABLE 28              INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2019–2023 (USD MILLION)            108

TABLE 29              INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2024–2029 (USD MILLION)            108

TABLE 30              INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 109

TABLE 31              INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 109

TABLE 32              INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2019–2023 (USD MILLION)            110

TABLE 33              INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY REGION, 2024–2029 (USD MILLION)            111

TABLE 34              RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS           112

TABLE 35              INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION)                 113

TABLE 36              INTERVENTIONAL ONCOLOGY MARKET FOR RADIOEMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION)                 114

TABLE 37              NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS 115

TABLE 38              INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2019–2023 (USD MILLION) 116

TABLE 39              INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY TYPE, 2024–2029 (USD MILLION) 116

TABLE 40              INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2019–2023 (USD MILLION) 117

TABLE 41              INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE EMBOLIC AGENTS, BY REGION, 2024–2029 (USD MILLION) 118

TABLE 42              INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION,

2019–2023 (USD MILLION)            120

TABLE 43              INTERVENTIONAL ONCOLOGY MARKET FOR MICROSPHERES, BY REGION,

2024–2029 (USD MILLION)            121

TABLE 44              INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION,

2019–2023 (USD MILLION)            123

TABLE 45              INTERVENTIONAL ONCOLOGY MARKET FOR COATED BEADS, BY REGION,

2024–2029 (USD MILLION)            124

TABLE 46              MAJOR BRANDS OF MICROCARRIERS     125

TABLE 47              INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION,

2019–2023 (USD MILLION)            126

TABLE 48              INTERVENTIONAL ONCOLOGY MARKET FOR MICROPARTICLES, BY REGION,

2024–2029 (USD MILLION)            127

TABLE 49              INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE,

2019–2023 (USD MILLION)            128

TABLE 50              INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE,

2024–2029 (USD MILLION)            128

TABLE 51              INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)                 129

TABLE 52              INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)                 130

TABLE 53              RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS 131

TABLE 54              INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION) 132

TABLE 55              INTERVENTIONAL ONCOLOGY MARKET FOR RADIOFREQUENCY ABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION) 133

TABLE 56              RADIOFREQUENCY ABLATION SYSTEMS, BY REGION,

2023–2029 (THOUSAND UNITS)  134

TABLE 57              INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES,

BY REGION, 2019–2023 (USD MILLION)   135

TABLE 58              INTERVENTIONAL ONCOLOGY MARKET FOR MICROWAVE ABLATION DEVICES,

BY REGION, 2024–2029 (USD MILLION)   136

TABLE 59              MICROWAVE ABLATION SYSTEMS, BY REGION, 2023–2029 (THOUSAND UNITS)  137

TABLE 60              INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2019–2023 (USD MILLION)            138

TABLE 61              INTERVENTIONAL ONCOLOGY MARKET FOR CRYOABLATION DEVICES, BY REGION, 2024–2029 (USD MILLION)            139

TABLE 62              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES,

BY REGION, 2019–2023 (USD MILLION)   141

TABLE 63              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER ABLATION DEVICES,

BY REGION, 2024–2029 (USD MILLION)   142

TABLE 64              INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE,

2019–2023 (USD MILLION)            143

TABLE 65              INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE,

2024–2029 (USD MILLION)            143

TABLE 66              INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2019–2023 (USD MILLION)                 144

TABLE 67              INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY REGION, 2024–2029 (USD MILLION)                 145

TABLE 68              INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION,

2019–2023 (USD MILLION)            147

TABLE 69              INTERVENTIONAL ONCOLOGY MARKET FOR MICROCATHETERS, BY REGION,

2024–2029 (USD MILLION)            148

TABLE 70              INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION,

2019–2023 (USD MILLION)            150

TABLE 71              INTERVENTIONAL ONCOLOGY MARKET FOR GUIDEWIRES, BY REGION,

2024–2029 (USD MILLION)            151

TABLE 72              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES,

BY REGION, 2019–2023 (USD MILLION)   152

TABLE 73              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER SUPPORT DEVICES,

BY REGION, 2024–2029 (USD MILLION)   153

TABLE 74              INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            155

TABLE 75              INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            155

TABLE 76              INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION,

2019–2023 (USD MILLION)            157

TABLE 77              INTERVENTIONAL ONCOLOGY MARKET FOR LIVER CANCER, BY REGION,

2024–2029 (USD MILLION)            158

TABLE 78              INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION,

2019–2023 (USD MILLION)            160

TABLE 79              INTERVENTIONAL ONCOLOGY MARKET FOR KIDNEY CANCER, BY REGION,

2024–2029 (USD MILLION)            161

TABLE 80              INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION,

2019–2023 (USD MILLION)            163

TABLE 81              INTERVENTIONAL ONCOLOGY MARKET FOR BREAST CANCER, BY REGION,

2024–2029 (USD MILLION)            164

TABLE 82              INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION,

2019–2023 (USD MILLION)            166

TABLE 83              INTERVENTIONAL ONCOLOGY MARKET FOR LUNG CANCER, BY REGION,

2024–2029 (USD MILLION)            167

TABLE 84              INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION,

2019–2023 (USD MILLION)            169

TABLE 85              INTERVENTIONAL ONCOLOGY MARKET FOR BONE CANCER, BY REGION,

2024–2029 (USD MILLION)            170

TABLE 86              INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2019–2023 (USD MILLION)                 172

TABLE 87              INTERVENTIONAL ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2024–2029 (USD MILLION)                 173

TABLE 88              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2019–2023 (USD MILLION)                 175

TABLE 89              INTERVENTIONAL ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2024–2029 (USD MILLION)                 176

TABLE 90              INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            178

TABLE 91              INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            178

TABLE 92              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT),

BY REGION, 2019–2023 (USD MILLION)   180

TABLE 93              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT),

BY REGION, 2024–2029 (USD MILLION)   181

TABLE 94              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2019–2023 (USD MILLION)   183

TABLE 95              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE), BY REGION, 2024–2029 (USD MILLION)   184

TABLE 96              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION,

2019–2023 (USD MILLION)            186

TABLE 97              INTERVENTIONAL ONCOLOGY MARKET FOR TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE), BY REGION,

2024–2029 (USD MILLION)            187

TABLE 98              INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION,

BY REGION, 2019–2023 (USD MILLION)   189

TABLE 99              INTERVENTIONAL ONCOLOGY MARKET FOR THERMAL TUMOR ABLATION,

BY REGION, 2024–2029 (USD MILLION)   190

TABLE 100            INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION,

BY REGION, 2019–2023 (USD MILLION)   192

TABLE 101            INTERVENTIONAL ONCOLOGY MARKET FOR NON-THERMAL TUMOR ABLATION,

BY REGION, 2024–2029 (USD MILLION)   193

TABLE 102            INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)     195

TABLE 103            INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)     195

TABLE 104            INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION,

2019–2023 (USD MILLION)            197

TABLE 105            INTERVENTIONAL ONCOLOGY MARKET FOR HOSPITALS, BY REGION,

2024–2029 (USD MILLION)            198

TABLE 106            INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2019–2023 (USD MILLION)                 200

TABLE 107            INTERVENTIONAL ONCOLOGY MARKET FOR SPECIALTY CLINICS, BY REGION, 2024–2029 (USD MILLION)                 201

TABLE 108            INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2023 (USD MILLION) 203

TABLE 109            INTERVENTIONAL ONCOLOGY MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2024–2029 (USD MILLION) 204

TABLE 110            INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2019–2023 (USD MILLION)          207

TABLE 111            INTERVENTIONAL ONCOLOGY MARKET, BY REGION, 2024–2029 (USD MILLION)          207

TABLE 112            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2019–2023 (USD MILLION)            209

TABLE 113            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2024–2029 (USD MILLION)            209

TABLE 114            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 209

TABLE 115            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 210

TABLE 116            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            210

TABLE 117            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            210

TABLE 118            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)                211

TABLE 119            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)                211

TABLE 120            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       211

TABLE 121            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       212

TABLE 122            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       212

TABLE 123            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       212

TABLE 124            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            213

TABLE 125            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            213

TABLE 126            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            214

TABLE 127            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            214

TABLE 128            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            215

TABLE 129            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            215

TABLE 130            US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2019–2023 (USD MILLION)            217

TABLE 131            US: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2024–2029 (USD MILLION)            217

TABLE 132            US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            217

TABLE 133            US: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            218

TABLE 134            US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         218

TABLE 135            US: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         218

TABLE 136            US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 219

TABLE 137            US: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 219

TABLE 138            US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 219

TABLE 139            US: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 220

TABLE 140            US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            220

TABLE 141            US: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            221

TABLE 142            US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            221

TABLE 143            US: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            222

TABLE 144            US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            222

TABLE 145            US: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            222

TABLE 146            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            223

TABLE 147            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            224

TABLE 148            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         224

TABLE 149            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         224

TABLE 150            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 225

TABLE 151            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 225

TABLE 152            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            225

TABLE 153            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            226

TABLE 154            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            226

TABLE 155            CANADA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            226

TABLE 156            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            227

TABLE 157            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            227

TABLE 158            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            228

TABLE 159            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            228

TABLE 160            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            229

TABLE 161            CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            229

TABLE 162            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2019–2023 (USD MILLION)            231

TABLE 163            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2024–2029 (USD MILLION)            231

TABLE 164            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            232

TABLE 165            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            232

TABLE 166            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         232

TABLE 167            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         233

TABLE 168            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 233

TABLE 169            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 233

TABLE 170            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            234

TABLE 171            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            234

TABLE 172            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            234

TABLE 173            EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            235

TABLE 174            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            235

TABLE 175            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            236

TABLE 176            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            236

TABLE 177            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            237

TABLE 178            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            237

TABLE 179            EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            238

TABLE 180            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            239

TABLE 181            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            240

TABLE 182            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 240

TABLE 183            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 240

TABLE 184            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 241

TABLE 185            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 241

TABLE 186            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         241

TABLE 187            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         242

TABLE 188            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         242

TABLE 189            GERMANY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         242

TABLE 190            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            243

TABLE 191            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            243

TABLE 192            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            244

TABLE 193            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            244

TABLE 194            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            245

TABLE 195            GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            245

TABLE 196            UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2019–2023 (USD MILLION)            246

TABLE 197            UK: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES,

2024–2029 (USD MILLION)            246

TABLE 198            UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            246

TABLE 199            UK: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            247

TABLE 200            UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         247

TABLE 201            UK: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         247

TABLE 202            UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 248

TABLE 203            UK: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 248

TABLE 204            UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 248

TABLE 205            UK: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 249

TABLE 206            UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            249

TABLE 207            UK: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            250

TABLE 208            UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            250

TABLE 209            UK: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            251

TABLE 210            UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            251

TABLE 211            UK: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            251

TABLE 212            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            252

TABLE 213            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            253

TABLE 214            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         253

TABLE 215            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         253

TABLE 216            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 254

TABLE 217            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 254

TABLE 218            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            254

TABLE 219            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            255

TABLE 220            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            255

TABLE 221            FRANCE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            255

TABLE 222            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            256

TABLE 223            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            256

TABLE 224            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            257

TABLE 225            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            257

TABLE 226            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            258

TABLE 227            FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            258

TABLE 228          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 259

TABLE 229          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 259

TABLE 230            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         259

TABLE 231            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         260

TABLE 232            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         260

TABLE 233            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         260

TABLE 234            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 261

TABLE 235            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 261

TABLE 236            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 261

TABLE 237            SPAIN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 262

TABLE 238          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            262

TABLE 239          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            263

TABLE 240          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            263

TABLE 241          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            264

TABLE 242          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            264

TABLE 243          SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            264

TABLE 244          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 265

TABLE 245          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 266

TABLE 246            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         266

TABLE 247            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         266

TABLE 248            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         267

TABLE 249            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         267

TABLE 250            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 267

TABLE 251            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 268

TABLE 252            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 268

TABLE 253            ITALY: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 268

TABLE 254          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            269

TABLE 255          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            269

TABLE 256          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            270

TABLE 257          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            270

TABLE 258          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            271

TABLE 259          ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            271

TABLE 260            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 272

TABLE 261            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 272

TABLE 262            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            272

TABLE 263            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            273

TABLE 264            REST OF EUROPE INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)                273

TABLE 265            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)                273

TABLE 266            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       274

TABLE 267            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       274

TABLE 268            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       274

TABLE 269            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       275

TABLE 270            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)            275

TABLE 271            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)            276

TABLE 272            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            276

TABLE 273            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            277

TABLE 274            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            277

TABLE 275            REST OF EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            277

TABLE 276            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2019–2023 (USD MILLION)            280

TABLE 277            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2024–2029 (USD MILLION)            280

TABLE 278            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 281

TABLE 279            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 281

TABLE 280            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 281

TABLE 281            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 282

TABLE 282            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 282

TABLE 283            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 282

TABLE 284            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         283

TABLE 285            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         283

TABLE 286            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         283

TABLE 287            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         284

TABLE 288            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            284

TABLE 289            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            285

TABLE 290            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            285

TABLE 291            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            286

TABLE 292            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            286

TABLE 293            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            287

TABLE 294          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 288

TABLE 295          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 289

TABLE 296            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         289

TABLE 297            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         289

TABLE 298            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         290

TABLE 299            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         290

TABLE 300            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 290

TABLE 301            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 291

TABLE 302            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 291

TABLE 303            JAPAN: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 291

TABLE 304          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            292

TABLE 305          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            292

TABLE 306          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            293

TABLE 307          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            293

TABLE 308          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            294

TABLE 309          JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            294

TABLE 310            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            295

TABLE 311            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            295

TABLE 312            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         295

TABLE 313            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         296

TABLE 314            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         296

TABLE 315            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         296

TABLE 316            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            297

TABLE 317            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            297

TABLE 318            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            297

TABLE 319            CHINA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            298

TABLE 320            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            298

TABLE 321            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            299

TABLE 322            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            299

TABLE 323            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            300

TABLE 324            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            300

TABLE 325            CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            300

TABLE 326          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 301

TABLE 327          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 302

TABLE 328            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         302

TABLE 329            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         302

TABLE 330            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2019–2023 (USD MILLION)         303

TABLE 331            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS,

BY TYPE, 2024–2029 (USD MILLION)         303

TABLE 332            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 303

TABLE 333            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 304

TABLE 334            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)                 304

TABLE 335            INDIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)                 304

TABLE 336          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            305

TABLE 337          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            305

TABLE 338          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            306

TABLE 339          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            306

TABLE 340          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            307

TABLE 341          INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            307

TABLE 342            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            308

TABLE 343            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            308

TABLE 344            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 308

TABLE 345            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 309

TABLE 346            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 309

TABLE 347            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 309

TABLE 348            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         310

TABLE 349            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         310

TABLE 350            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         310

TABLE 351            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         311

TABLE 352            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            311

TABLE 353            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            312

TABLE 354            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            312

TABLE 355            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            313

TABLE 356            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            313

TABLE 357            AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            314

TABLE 358            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 314

TABLE 359            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 315

TABLE 360            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION) 315

TABLE 361            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION) 315

TABLE 362            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 316

TABLE 363            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 316

TABLE 364            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         316

TABLE 365            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         317

TABLE 366            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         317

TABLE 367            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         317

TABLE 368            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            318

TABLE 369            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            318

TABLE 370            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            319

TABLE 371            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            319

TABLE 372            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            320

TABLE 373            SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            320

TABLE 374            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 321

TABLE 375            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 321

TABLE 376            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            321

TABLE 377            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            322

TABLE 378            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)            322

TABLE 379            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)            322

TABLE 380            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       323

TABLE 381            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       323

TABLE 382            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       323

TABLE 383            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       324

TABLE 384            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)            324

TABLE 385            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)            325

TABLE 386            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)            325

TABLE 387            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)            326

TABLE 388            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)                 326

TABLE 389            REST OF ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)                 327

TABLE 390            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2019–2023 (USD MILLION)            327

TABLE 391            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY,

2024–2029 (USD MILLION)            328

TABLE 392            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 328

TABLE 393            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 328

TABLE 394            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            329

TABLE 395            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            329

TABLE 396            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)                329

TABLE 397            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)                330

TABLE 398            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       330

TABLE 399            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       330

TABLE 400            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       331

TABLE 401            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       331

TABLE 402            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            331

TABLE 403            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            332

TABLE 404            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            332

TABLE 405            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            333

TABLE 406            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            333

TABLE 407            LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            334

TABLE 408            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            335

TABLE 409            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            336

TABLE 410            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         336

TABLE 411            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         336

TABLE 412            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 337

TABLE 413            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 337

TABLE 414            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            337

TABLE 415            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            338

TABLE 416            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            338

TABLE 417            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            338

TABLE 418            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            339

TABLE 419            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            339

TABLE 420            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            340

TABLE 421            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            340

TABLE 422            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            341

TABLE 423            BRAZIL: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            341

TABLE 424            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)            342

TABLE 425            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)            342

TABLE 426            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2019–2023 (USD MILLION)         342

TABLE 427            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES,

BY TYPE, 2024–2029 (USD MILLION)         343

TABLE 428            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION) 343

TABLE 429            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION) 343

TABLE 430            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            344

TABLE 431            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            344

TABLE 432            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)            344

TABLE 433            MEXICO: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)            345

TABLE 434            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            345

TABLE 435            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            346

TABLE 436            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            346

TABLE 437            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            347

TABLE 438            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            347

TABLE 439            MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            348

TABLE 440            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 348

TABLE 441            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 349

TABLE 442            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            349

TABLE 443            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            349

TABLE 444            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)            350

TABLE 445            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)            350

TABLE 446            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       350

TABLE 447            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       351

TABLE 448            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       351

TABLE 449            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       351

TABLE 450            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY CANCER TYPE, 2019–2023 (USD MILLION)       352

TABLE 451            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET,

BY CANCER TYPE, 2024–2029 (USD MILLION)       352

TABLE 452            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)            353

TABLE 453            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)            353

TABLE 454            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)                 354

TABLE 455            REST OF LATIN AMERICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)                 354

TABLE 456            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2023 (USD MILLION)                 355

TABLE 457            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2024–2029 (USD MILLION)                 355

TABLE 458            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 355

TABLE 459            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 356

TABLE 460            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            356

TABLE 461            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            356

TABLE 462            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)            357

TABLE 463            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)                357

TABLE 464            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       357

TABLE 465            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       358

TABLE 466            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       358

TABLE 467            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       358

TABLE 468            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2019–2023 (USD MILLION)            359

TABLE 469            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE, 2024–2029 (USD MILLION)            359

TABLE 470            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2023 (USD MILLION)            360

TABLE 471            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2024–2029 (USD MILLION)            360

TABLE 472            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2019–2023 (USD MILLION)                 361

TABLE 473            MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET, BY END USER, 2024–2029 (USD MILLION)                 361

TABLE 474            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 363

TABLE 475            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 363

TABLE 476            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)            364

TABLE 477            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)            364

TABLE 478            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)                364

TABLE 479            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)                365

TABLE 480            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)       365

TABLE 481            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)       365

TABLE 482            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)       366

TABLE 483            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)       366

TABLE 484            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2019–2023 (USD MILLION)            366

TABLE 485            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE,

2024–2029 (USD MILLION)            367

TABLE 486            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2019–2023 (USD MILLION)            367

TABLE 487            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE,

2024–2029 (USD MILLION)            368

TABLE 488            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2019–2023 (USD MILLION)            368

TABLE 489            GCC COUNTRIES: INTERVENTIONAL ONCOLOGY MARKET, BY END USER,

2024–2029 (USD MILLION)            369

TABLE 490            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2019–2023 (USD MILLION)                 369

TABLE 491            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY DEVICES & CONSUMABLES, 2024–2029 (USD MILLION)                 370

TABLE 492            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)     370

TABLE 493            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR EMBOLIZATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)     370

TABLE 494            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2019–2023 (USD MILLION)            371

TABLE 495            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR

NON-RADIOACTIVE AGENTS, BY TYPE, 2024–2029 (USD MILLION)            371

TABLE 496            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2019–2023 (USD MILLION)     371

TABLE 497            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR ABLATION DEVICES, BY TYPE, 2024–2029 (USD MILLION)     372

TABLE 498            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2023 (USD MILLION)     372

TABLE 499            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET FOR SUPPORT DEVICES, BY TYPE, 2024–2029 (USD MILLION)     372

TABLE 500            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY CANCER TYPE, 2019–2023 (USD MILLION)       373

TABLE 501            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY CANCER TYPE, 2024–2029 (USD MILLION)       373

TABLE 502            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY PROCEDURE, 2019–2023 (USD MILLION)          374

TABLE 503            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY PROCEDURE, 2024–2029 (USD MILLION)          374

TABLE 504            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY END USER, 2019–2023 (USD MILLION)               375

TABLE 505            REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL ONCOLOGY MARKET,

BY END USER, 2024–2029 (USD MILLION)               375

TABLE 506            STRATEGIES ADOPTED BY KEY PLAYERS IN INTERVENTIONAL ONCOLOGY MARKET, JANUARY 2021–DECEMBER 2024                377

TABLE 507            INTERVENTIONAL ONCOLOGY MARKET: DEGREE OF COMPETITION         380

TABLE 508            INTERVENTIONAL ONCOLOGY MARKET: REGION FOOTPRINT     385

TABLE 509            INTERVENTIONAL ONCOLOGY MARKET: DEVICES & CONSUMABLES FOOTPRINT                386

TABLE 510            INTERVENTIONAL ONCOLOGY MARKET: CANCER TYPE FOOTPRINT         387

TABLE 511            INTERVENTIONAL ONCOLOGY MARKET: PROCEDURE FOOTPRINT            389

TABLE 512            INTERVENTIONAL ONCOLOGY MARKET: END USER FOOTPRINT            390

TABLE 513            INTERVENTIONAL ONCOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/

SMES, 2023           393

TABLE 514            INTERVENTIONAL ONCOLOGY MARKET: COMPETITIVE BENCHMARKING

OF KEY STARTUPS/SMES              393

TABLE 515            INTERVENTIONAL ONCOLOGY MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024     396

TABLE 516            INTERVENTIONAL ONCOLOGY MARKET: DEALS, JANUARY 2021–DECEMBER 2024 396

TABLE 517            INTERVENTIONAL ONCOLOGY MARKET: EXPANSIONS,

JANUARY 2021–DECEMBER 2024 398

TABLE 518            SIEMENS HEALTHINEERS AG (VARIAN): COMPANY OVERVIEW   399

TABLE 519            SIEMENS HEALTHINEERS AG (VARIAN): PRODUCTS/SOLUTIONS/

SERVICES OFFERED        400

TABLE 520            SIEMENS HEALTHINEERS AG (VARIAN): PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024                401

TABLE 521            SIEMENS HEALTHINEERS AG (VARIAN): DEALS, JANUARY 2021–DECEMBER 2024 401

TABLE 522            BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW   404

TABLE 523            BOSTON SCIENTIFIC CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED    405

TABLE 524            BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–DECEMBER 2024 406

TABLE 525            BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021–DECEMBER 2024 407

TABLE 526            MEDTRONIC: COMPANY OVERVIEW       408

TABLE 527            MEDTRONIC: PRODUCTS/SOLUTIONS/SERVICES OFFERED    409

TABLE 528            TERUMO CORPORATION: COMPANY OVERVIEW          412

TABLE 529            TERUMO CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED    413

TABLE 530            TERUMO CORPORATION: EXPANSIONS, JANUARY 2021– DECEMBER 2024                414

TABLE 531            MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW          415

TABLE 532            MERIT MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED    416

TABLE 533            MERIT MEDICAL SYSTEMS: EXPANSIONS, JANUARY 2021– DECEMBER 2024                417

TABLE 534            JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY OVERVIEW   419

TABLE 535            JOHNSON & JOHNSON MEDTECH (ETHICON): PRODUCTS/SOLUTIONS/

SERVICES OFFERED        420

TABLE 536            TELEFLEX INCORPORATED: COMPANY OVERVIEW          421

TABLE 537            TELEFLEX INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED    422

TABLE 538            ANGIODYNAMICS: COMPANY OVERVIEW                 423

TABLE 539            ANGIODYNAMICS: PRODUCTS/SOLUTIONS/SERVICES OFFERED    424

TABLE 540            ANGIODYNAMICS: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–DECEMBER 2024 425

TABLE 541            STRYKER: COMPANY OVERVIEW               426

TABLE 542            STRYKER: PRODUCTS/SOLUTIONS/SERVICES OFFERED             427

TABLE 543            IMBIOTECHNOLOGIES LTD.: COMPANY OVERVIEW          428

TABLE 544            IMBIOTECHNOLOGIES LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED    428

TABLE 545            COOK: COMPANY OVERVIEW    429

TABLE 546            COOK: PRODUCTS/SOLUTIONS/SERVICES OFFERED             429

TABLE 547            ICECURE MEDICAL: COMPANY OVERVIEW                 430

TABLE 548            ICECURE MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED    431

TABLE 549            ICECURE MEDICAL LTD.: PRODUCT APPROVALS        432

TABLE 550            ICECURE MEDICAL LTD.: DEALS               432

TABLE 551            MEDWAVES, INC.: COMPANY OVERVIEW                 434

TABLE 552            MEDWAVES INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED    434

TABLE 553            PROFOUND MEDICAL: COMPANY OVERVIEW                 435

TABLE 554            PROFOUND MEDICAL: PRODUCTS/SOLUTIONS/SERVICES OFFERED    435

TABLE 555            RF MEDICAL CO., LTD.: COMPANY OVERVIEW                 436

TABLE 556            RF MEDICAL CO., LTD.: PRODUCTS/SOLUTIONS/SERVICES OFFERED    436

TABLE 557            MINIMAX MEDICAL LIMITED: COMPANY OVERVIEW          437

TABLE 558            MINIMAX MEDICAL LIMITED: PRODUCTS/SOLUTIONS/SERVICES OFFERED    437

TABLE 559            ABK BIOMEDICAL INC.: COMPANY OVERVIEW                 438

TABLE 560            ABK BIOMEDICAL INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED    438

TABLE 561            OLYMPUS CORPORATION: COMPANY OVERVIEW          439

TABLE 562            OLYMPUS CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED    440

TABLE 563            SURGNOVA: COMPANY OVERVIEW         441

TABLE 564            SURGNOVA: PRODUCTS/SOLUTIONS/SERVICES OFFERED             441

TABLE 565            STARMED AMERICA: COMPANY OVERVIEW                 442

TABLE 566            STARMED AMERICA: PRODUCTS/SOLUTIONS/SERVICES OFFERED    442

TABLE 567            SIRTEX SIR-SPHERES PTY LTD.: COMPANY OVERVIEW          443

TABLE 568            GUERBET: COMPANY OVERVIEW             444

TABLE 569            ACCURAY: COMPANY OVERVIEW             445

TABLE 570            EMBOLX, INC.: COMPANY OVERVIEW    446

TABLE 571            SONABLATE CORP.: COMPANY OVERVIEW                 447

LIST OF FIGURES

FIGURE 1              INTERVENTIONAL ONCOLOGY MARKET SEGMENTATION              40

FIGURE 2              RESEARCH DESIGN         44

FIGURE 3              PRIMARY SOURCES         47

FIGURE 4              BREAKDOWN OF INTERVIEWS WITH EXPERTS: SUPPLY-SIDE AND

DEMAND-SIDE PARTICIPANTS  49

FIGURE 5              BREAKDOWN OF INTERVIEWS WITH EXPERTS (SUPPLY SIDE):

BY COMPANY TYPE, DESIGNATION, AND REGION            50

FIGURE 6              BREAKDOWN OF INTERVIEWS WITH EXPERTS (DEMAND SIDE):

BY END USER, DESIGNATION, AND REGION        50

FIGURE 7              SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS         51

FIGURE 8              REVENUE SHARE ANALYSIS ILLUSTRATION: SIEMENS HEALTHINEERS AG (2023)         52

FIGURE 9              SUPPLY-SIDE MARKET SIZE ESTIMATION: INTERVENTIONAL

ONCOLOGY MARKET (2023)        53

FIGURE 10            TOP-DOWN APPROACH                53

FIGURE 11            ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND

CHALLENGES (2024–2029)             55

FIGURE 12            CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 56

FIGURE 13            DATA TRIANGULATION METHODOLOGY                 57

FIGURE 14            EMBOLIZATION DEVICES SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)        60

FIGURE 15            LIVER CANCER TYPE SEGMENT TO LEAD MARKET DURING FORECAST

PERIOD (USD MILLION)                61

FIGURE 16            THERMAL TUMOR ABLATION SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD (USD MILLION)            62

FIGURE 17            HOSPITALS SEGMENT TO DOMINATE INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD (USD MILLION)                63

FIGURE 18            NORTH AMERICA ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023                 64

FIGURE 19            GROWING DEMAND FOR INTERVENTIONAL ONCOLOGY TO DRIVE MARKET                65

FIGURE 20            EMBOLIZATION DEVICES ACCOUNTED FOR LARGEST SHARE OF INTERVENTIONAL ONCOLOGY MARKET IN 2023        66

FIGURE 21            CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD         67

FIGURE 22            NORTH AMERICA TO DOMINATE MARKET DURING FORECAST PERIOD       67

FIGURE 23            EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES

DURING FORECAST PERIOD       68

FIGURE 24            DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN

INTERVENTIONAL ONCOLOGY MARKET              69

FIGURE 25            VALUE CHAIN ANALYSIS: MAXIMUM VALUE ADDED DURING

MANUFACTURING PHASE            75

FIGURE 26            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EMBOLIZATION DEVICES, ABLATION DEVICES, AND SUPPORT DEVICES               79

FIGURE 27            KEY BUYING CRITERIA FOR EMBOLIZATION DEVICES, ABLATION DEVICES,

AND SUPPORT DEVICES               80

FIGURE 28            PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES      85

FIGURE 29            CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES                86

FIGURE 30            EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES              88

FIGURE 31            REVENUE SHIFT IN INTERVENTIONAL ONCOLOGY MARKET     93

FIGURE 32            PATENT PUBLICATION TRENDS, JANUARY 2014–DECEMBER 2024     93

FIGURE 33            TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR INTERVENTIONAL ONCOLOGY, JANUARY 2014–DECEMBER 2024 94

FIGURE 34            TOP APPLICANT JURISDICTIONS FOR INTERVENTIONAL ONCOLOGY PATENTS, JANUARY 2014–DECEMBER 2024                94

FIGURE 35            AVERAGE SELLING PRICE OF INTERVENTIONAL ONCOLOGY DEVICES,

BY KEY PLAYER, 2023      97

FIGURE 36            END USER EXPECTATIONS IN EMBOLIZATION DEVICES, ABLATION DEVICES,

AND SUPPORT DEVICES               101

FIGURE 37            INTERVENTIONAL ONCOLOGY MARKET: ECOSYSTEM       103

FIGURE 38            INTERVENTIONAL ONCOLOGY MARKET: SUPPLY CHAIN ANALYSIS             105

FIGURE 39            ADJACENT MARKETS TO INTERVENTIONAL ONCOLOGY MARKET     105

FIGURE 40            INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL ONCOLOGY MARKET, 2020–2023         106

FIGURE 41            CHINA TO GROW AT HIGHEST CAGR IN INTERVENTIONAL ONCOLOGY MARKET DURING FORECAST PERIOD                206

FIGURE 42            NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT             208

FIGURE 43            EUROPE: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT       230

FIGURE 44            ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT       279

FIGURE 45            REVENUE SHARE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL

ONCOLOGY MARKET,2019−2023               378

FIGURE 46            INTERVENTIONAL ONCOLOGY MARKET SHARE ANALYSIS, BY KEY PLAYER, 2023                 379

FIGURE 47            INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       383

FIGURE 48            INTERVENTIONAL ONCOLOGY MARKET: COMPANY FOOTPRINT 384

FIGURE 49            INTERVENTIONAL ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                 392

FIGURE 50            EV/EBITDA OF KEY VENDORS   394

FIGURE 51            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                394

FIGURE 52            INTERVENTIONAL ONCOLOGY MARKET: COMPARATIVE BRAND ANALYSIS            395

FIGURE 53            SIEMENS HEALTHINEERS AG (VARIAN): COMPANY SNAPSHOT (2024)      400

FIGURE 54            BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)      405

FIGURE 55            MEDTRONIC: COMPANY SNAPSHOT (2024)                 409

FIGURE 56            TERUMO CORPORATION: COMPANY SNAPSHOT (2024)             413

FIGURE 57            MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2023)             416

FIGURE 58            JOHNSON & JOHNSON MEDTECH (ETHICON): COMPANY SNAPSHOT (2023)      420

FIGURE 59            TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023)             422

FIGURE 60            ANGIODYNAMICS: COMPANY SNAPSHOT (2024)                 424

FIGURE 61            STRYKER: COMPANY SNAPSHOT (2023) 427

FIGURE 62            ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)    431

FIGURE 63            OLYMPUS CORPORATION: COMPANY SNAPSHOT (2024)             440

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧